30 January 2021 : Clinical Research
Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
Naibo Hu12DE, Tiejun Qin1B, Xiaoyan Du3C, Bingyi Wang3DE, Xiaoyun Wang3E, Zefeng Xu1DF, Lijuan Pan1F, Shiqiang Qu1DF, Zhijian Xiao1A*DOI: 10.12659/MSM.928454
Med Sci Monit 2021; 27:e928454
Table 2 Frequencies of identified mutations.
| Gene | Azacitidine group (n=38) | Decitabine group (n=120) | P value |
|---|---|---|---|
| ASXL1 (%) | 2 (5.3) | 17 (14.2) | 0.236 |
| BRAF (%) | 0 (0.0) | 3 (2.5) | 0.763 |
| CEBPA (%) | 0 (0.0) | 5 (4.2) | 0.455 |
| DNMT3A (%) | 1 (2.6) | 7 (5.8) | 0.719 |
| EZH2 (%) | 1 (2.6) | 2 (1.7) | 0.999 |
| FAT1 (%) | 4 (10.5) | 15 (12.5) | 0.968 |
| FLT3 (%) | 0 (0.0) | 2 (1.7) | 0.999 |
| GATA (%) | 2 (5.3) | 0 (0.0) | 0.090 |
| IDH1 (%) | 2 (5.3) | 4 (3.3) | 0.956 |
| IDH2 (%) | 1 (2.6) | 5 (4.2) | 0.999 |
| JAK2 (%) | 3 (7.9) | 4 (3.3) | 0.460 |
| KIT (%) | 0 (0.0) | 2 (1.7) | 0.999 |
| KRAS (%) | 0 (0.0) | 4 (3.3) | 0.584 |
| MPL (%) | 0 (0.0) | 3 (2.5) | 0.763 |
| NPM1 (%) | 1 (2.6) | 4 (3.3) | 0.999 |
| NRAS (%) | 0 (0.0) | 9 (7.5) | 0.181 |
| RUNX1 (%) | 2 (5.3) | 13 (10.8) | 0.482 |
| SRSF2 (%) | 2 (5.3) | 4 (3.3) | 0.956 |
| TET2 (%) | 4 (10.5) | 5 (4.2) | 0.283 |
| TP53 (%) | 1 (2.6) | 19 (15.8) | 0.064 |
| U2AF1 (%) | 3 (7.9) | 13 (10.8) | 0.830 |
| WT1 (%) | 1 (2.6) | 3 (2.5) | 0.999 |